Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St futures rise as Fed rate hike lifts long-standing overhang
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Vanda Pharmaceuticals (VNDA) Reports Q2 EPS of $0.21, Revenues Beat; Offers FY19 HETLIOZ & Fanapt Combined Sales Outlook
July 31, 2019 5:31 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.21, versus $0.00 reported last year. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $54.15 million.
Reported net income applicable to common stockholders of $8.2 million, or $0.06 per diluted share, for the quarter ended June 30, 2019, as compared with $10.9 million, or $0.09 per diluted share, for the quarter ended June 30, 2018;Achieved Core Funds From Operations ("Core FFO") of $0.43 per diluted share for the quarter ended June 30, 2019, as compared with $0.41 per diluted share for the quarter ended June 30, 2018;Completed approximately 517,000 square feet of leasing during... More